MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9199
+0.0651
+7.62%
Closed 16:00 10/17 EDT
OPEN
0.8500
PREV CLOSE
0.8548
HIGH
0.9480
LOW
0.8100
VOLUME
589.28K
TURNOVER
--
52 WEEK HIGH
6.51
52 WEEK LOW
0.7140
MARKET CAP
7.46M
P/E (TTM)
-0.2379
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ONTX News

  • The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
  • Benzinga.6d ago
  • The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
  • Benzinga.10/10 11:31
  • The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
  • Benzinga.10/09 11:58
  • The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
  • Benzinga.10/04 11:32

More

Industry

Pharmaceuticals
+0.57%
Pharmaceuticals & Medical Research
+0.62%

Hot Stocks

Name
Price
%Change

About ONTX

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
More

Webull offers Onconova Therapeutics Inc (ONTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.